TrialCancer medicine2020

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.

Patrick Wayne Cobb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.